<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13261">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01886807</url>
  </required_header>
  <id_info>
    <org_study_id>Apneic Oxygenation</org_study_id>
    <nct_id>NCT01886807</nct_id>
  </id_info>
  <brief_title>The Use of Apneic Oxygenation During Prolonged Intubation in Pediatric Patients: a Randomized Clinical Trial</brief_title>
  <official_title>The Use of Apneic Oxygenation During Prolonged Intubation in Pediatric Patients: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient demographics (age, height and weight) will be collected for 546 consecutive patients
      presenting for dental restoration under general anesthesia. The baseline saturation will be
      recorded. The induction of anesthesia will be standardized for all patients. All patients
      will undergo an inhalational induction administered by face mask. After inserting an
      intravenous (IV) line, rocuronium will be administered. Intravenous propofol and fentanyl
      could be added at the discretion of the anesthesiologist. The patients will be mask
      ventilated then be with a mixture of Air/Oxygen (O2) to achieve an FiO2 of 0.3 for 3 minutes
      after the administration of rocuronium.

      Patients will be randomly assigned to one of three groups for the purpose of airway
      management: 1) direct laryngoscopy for nasotracheal intubation without oxygen insufflation
      (DL group); 2) direct laryngoscopy for nasotracheal intubation with oxygen insufflation
      (DLO2 Group); and 3) nasotracheal intubation using the Truview PCD video laryngoscope (VL
      Group). Computer-generated treatment allocations (using the PLAN procedure in SAS
      statistical software, using random-sized blocks) will be maintained in sequentially numbered
      sealed envelopes that will be opened after consent is obtained. The laryngoscopy and
      intubations will be performed by the study investigators who are faculty anesthesiologists
      or by the mid-level or resident or fellow working with them.

      The study will be stopped when:

        -  the patient will be intubated and a CO2 trace is obtained on the capnography or

        -  if the patient desaturates to 90%

        -  or if the patient shows signs of cardiac instability (ectopic beats, arrhythmia or
           hypotension)

      Randomized groups will be compared for balance on potentially confounding baseline variables
      using descriptive statistics. Primary outcome: In the primary hypothesis, desaturation will
      be characterized using both time to 1% saturation drop from the baseline and the rate
      (slope) of desaturation after an initial 1% drop. We will consider a given intubation
      technique (DLO2 or VL) better than DL on controlling saturation if found noninferior (i.e.,
      not worse) on both outcomes and superior on at least one of the outcomes. Thus our primary
      hypothesis will be assessed in a joint hypothesis testing framework described by Mascha and
      Turan. We a-priori define the non-inferiority delta for the outcome time to 1% drop as 5
      seconds (or 1.05 if using hazard ratio) and the slope delta as 0.05 percent per second.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary outcomes:

      Secondary-1. We will conduct tests for superiority to compare the Truview and DL with oxygen
      cannula methods on each of the two primary outcomes, and report the treatment effect
      estimates and adjusted confidence intervals.  Notably, the study is not powered to be able
      to assess equivalence between these two oxygen techniques.

      Secondary-2. We will compare the three randomized groups on total desaturation slope (rate)
      using a random slope linear mixed effects model with repeated measures. This model will
      allow accounting for the variability of the saturation rate for the patients and possible
      correlation of the saturation measurements within a patient (autoregressive correlation). We
      only will use saturation data before it reaches 90%.

      Secondary-3. We will assess the relative efficacy of Truview and DL with oxygen cannula in
      preventing 90% saturation compared with DL alone using 2-tailed chi-square tests of
      proportions (for superiority), summarized with a relative risk and confidence interval.

      Secondary -4: We will assess the correlation between the rate of desaturation and both age
      and body mass index, independent of randomized group. This will be done in the context of a
      random slope model as in the primary aim, assessing the interaction between the mean
      desaturation slope and each of age and body mass index.

      To restrict overall Type I error of the secondary hypotheses at 5% we will apply Bonferroni
      correction for multiple inferences and adjustment for interim analyses.

      Interim analyses will be conducted every 25% of the maximum planned enrollment using a
      groups sequential design to test for efficacy and futility.  We will use a gamma spending
      function (gamma = -4 for efficacy and -2 for futility) to maintain the significance level
      for the primary outcome at 2.5% and the power at 90% across the interim analyses.
      Significance criteria for all tests will be adjusted for interim analyses based on the
      above-mentioned gamma spending function and the corresponding z-statistic at teach interim
      look.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>From start of intubation attempt to completion of intubation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In the primary hypothesis, desaturation will be characterized using both time to 1% saturation drop from the baseline and the rate (slope) of desaturation after an initial 1% drop.We will consider a given intubation technique (DLO2 or VL) better than DL on controlling saturation if found noninferior (i.e., not worse) on both outcomes and superior on at least one of the outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>From start of intubation attempt to completion of intubation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>From start of intubation attempt to completion of intubation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation Duration</measure>
    <time_frame>From start of intubation attempt to completion of intubation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>At the completion of intubation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Intubation of Pediatric Dental Surgery Patients</condition>
  <arm_group>
    <arm_group_label>(DL group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>direct laryngoscopy for nasotracheal intubation without oxygen insufflation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(DL-O2 Group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>direct laryngoscopy for nasotracheal intubation with oxygen insufflation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(VL Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nasotracheal intubation using the Truview PCD video laryngoscope</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TrueView PCD Video Laryngoscope</intervention_name>
    <arm_group_label>(DL group)</arm_group_label>
    <arm_group_label>(DL-O2 Group)</arm_group_label>
    <arm_group_label>(VL Group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children scheduled for dental restoration under general nasotracheal anesthesia

          -  Patient age 1-17 years

          -  American Society of Anesthesiology physical status I, II, III.

        Exclusion Criteria:

          -  Patients at risk of pulmonary aspiration

          -  Patient with known or suspected difficult airway

          -  Respiratory infections/disease

          -  Congenital heart disease

          -  Hemodynamic instability

          -  Patients with known latex allergy

          -  Increased intracranial pressure

          -  Patients with known or suspected basilar skull fracture

          -  American Society of Anesthesiology physical status â‰¥ IV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Steiner, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roxana Ploski</last_name>
    <phone>214-456-8559</phone>
    <email>roxana.ploski@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanna Dela Cruz</last_name>
    <phone>214-456-8559</phone>
    <email>joanna.delacruz@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Steiner, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Szmuk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Olomu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Zhong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shahid Hussain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Setiawan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Kravitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edgar Kiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>June 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Peter Szmuk</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
